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Background: Podocytes are highly specialized cells integral to the normal functioning kid-
ney, however, in diabetic nephropathy injury occurs leading to a compromised phenotype
and podocyte dysfunction which critically produces podocyte loss with subsequent renal
impairment. TGFβ1 holds a major role in the development of diabetic nephropathy. Erk5 is
an atypical mitogen-activated protein (MAP) kinase involved in pathways modulating cell
survival, proliferation, differentiation, andmotility. Accordingly, the role of Erk5 in mediating
TGFβ1-induced podocyte damage was investigated.
Methods: Conditionally immortalized human podocytes were stimulated with TGFβ1
(2.5 ng/ml); inhibition of Erk5 activationwas conductedwith the chemical inhibitor BIX02188
(10 μM) directed to the upstream Mek5; inhibition of Alk5 was performed with SB431542
(10 μM); Ras signaling was inhibited with farnesylthiosalicylic acid (10 μM). Intracellular
signaling proteins were investigated by western blotting; phenotype was explored by
immunoﬂuorescence; proliferationwas assessedwith aMTS assay; motility was examined
with a scratch assay; barrier function was studied using electric cell-substrate impedance
sensing; apoptosis was studied with annexin V-FITC ﬂow cytometry.
Results: Podocytes expressed Erk5 which was phosphorylated byTGFβ1 via Mek5, whilst
not involving Ras. TGFβ1 altered podocyte phenotype by decreasing P-cadherin staining
and increasing α-SMA, as well as reducing podocyte barrier function; both were prevented
by inhibiting Erk5 phosphorylation with BIX02188. TGFβ1-induced podocyte proliferation
was prevented by BIX02188, whereas the induced apoptosis was not. Podocyte motility
was reduced by BIX02188 alone and further diminished with TGFβ1 co-incubation.
Conclusion:These results describe for the ﬁrst time the expression of Erk5 in podocytes
and identify it as a potential target for the treatment of diabetic renal disease.
Keywords:TGF-beta, Erk5, podocytes, diabetic nephropathies, barrier function, apoptosis, migration
INTRODUCTION
The rising tide of diabetic nephropathy with all its well docu-
mented health and economic consequences are the subject of a
great deal of interest to scientists, clinicians, service providers,
health service funders, and most importantly patients. There is
strong epidemiological evidence asserting that poor glycaemic
control is an important risk factor in the development of dia-
betic nephropathy, yet this clearly is a difﬁcult target to achieve on
a large scale (Fioretto et al., 2006). The additional fact that a subset
of patients with poor glycaemic control do not develop nephropa-
thy testiﬁes to amore complex nature of the disease. In the absence
of targeted education and support to markedly improve glycaemic
control in patients with diabetes, targeting downstream mediators
of the disease becomes an attractive option.
The powerful pro-ﬁbrogenic growth factor TGFβ1 is involved
in a variety of processes that cover apoptosis, migration, adhesion,
differentiation, and anti-proliferative responses, but crucially it
also plays a pivotal role in the development of diabetic nephropa-
thy where it has been shown to accumulate in injured kidneys
(Khalil, 1999; Reeves and Andreoli, 2000; Goldfarb and Ziyadeh,
2001; Siegel and Massagué, 2003; Chuang and He, 2009). The
aberrant secretion and activation of TGFβ1 results in excess
extracellular matrix (ECM) accumulation through activating the
transcription of ECM genes (type I collagen, type IV collagen,
ﬁbronectin, and laminin) thereby leading to glomerulosclerosis,
and further to the direct stimulation of ECM proteins TGFβ1 has
a key role in causing the secretion of additional pro-ﬁbrotic growth
factors such as connective tissue growth factor (CCN2/CTGF)
which compounds the matter (Ziyadeh et al., 1994; Phanish et al.,
2005; Niculescu-Duvaz et al., 2007). The potent pleiotropic TGFβ1
cytokine can alter cell phenotype with the consequence of impair-
ing organ function through mechanisms regulating intercellular
communication by altering the expression of the cadherin class of
junctional proteins (Maeda et al., 2005), as well as by changing cell
morphology via directly regulating the actin cytoskeleton (Var-
douli et al., 2008). Critical components of the diabetic milieu, glu-
cose, and advanced glycation end-products (AGEs), induce TGFβ1
expression in human diabetic nephropathy (Iwano et al., 1996) as
well as in mesangial cells (Ziyadeh et al., 1998; Kim et al., 2001)
and proximal tubule epithelial cells in culture (Rocco et al., 1992).
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Furthermore, podocytes increase TGFβ1 expression in diabetic
glomerulosclerosis and in animal models of diabetic renal disease
(Wahab et al., 2005).
The podocyte is a unique cell type which can be seen as
a specialized renal pericyte. Resting on the glomerular base-
ment membrane their interdigitating foot processes encapsulate
the capillaries of the glomerulus. Formed between these exten-
sions exists a specialized intercellular junction termed the slit
diaphragm that is composed of a multitude of proteins includ-
ing nephrin, P-cadherin, and podocalyxin which imbues the
podocyte with its size- and charge-selective nature and thereby
functions as a critical regulator of glomerular ﬁltration (Paven-
städt et al., 2003). In recent years considerable attention has
focused on the role of podocytes in diabetic nephropathy and
mounting evidence suggests that they play a key role in the
disease (Li et al., 2007; Herbach et al., 2009). The widening of
foot processes and nephrin loss in response to diabetic stim-
uli results in foot process effacement and podocyte detachment
(Binder et al., 1999; Li et al., 2007). Moreover, the podocy-
topaenia observed in diabetic nephropathy is due to podocyte
apoptosis in which TGFβ1 is crucially culpable where it induces
apoptosis of cultured murine podocytes (Schiffer et al., 2001).
Although podocyte loss in urine has been detected in patients with
diabetes, there is some controversy whether absolute podocyte
number is important rather than podocyte density (Dalla Ves-
tra et al., 2003). Normally a terminally differentiated cell type,
mature podocytes do not proliferate and are unable to recon-
stitute the loss that is observed in disease; however, maladap-
tive podocyte proliferation has been detected in different renal
pathologies such as cellular focal segmental glomerulosclerosis
and has been reported to be stimulated by TGFβ1 in vitro (Li
et al., 2007).
The multiple and varied effects of TGFβ1 are, in part, related to
the variety of intracellular signaling cascades that are stimulated
following the binding of TGFβ1 to its heterotetrameric receptor
complex which is formed from the dimerisation of type I and
type II receptors, namely Alk5 and Alk1 (Huang and Chen, 2012).
The canonical signaling that follows is mediated by the Smad
family of signaling molecules (Smad2/3 and Smad4), however,
this pathway has proved difﬁcult to target with small molecule
inhibitors and hence attention has moved to non-canonical sig-
naling such as the mitogen-activated protein (MAP) kinases. The
atypical MAP kinase Erk5 lies central to a variety of fundamental
cellular processes including cell survival, proliferation, differen-
tiation, and motility which overlap with the cellular processes
that become defective in diabetic nephropathy (Drew et al., 2012).
Erk5 activity was found to be modiﬁed in the glomeruli of an
animal model of type 2 diabetes mellitus indicating its dysregu-
lation in disease (Suzaki et al., 2004). In 2008 our group reported
the activation of Erk5 by TGFβ1 in human renal tubule epithe-
lial cells (Browne et al., 2008), and in the same year Dorado
et al. (2008) reported that TGFβ1-induced collagen I produc-
tion in mesangial cells was regulated by Erk5. To date there
exists no published data on the expression of Erk5 in podocytes
along with its possible involvement in TGFβ1-mediated signal-
ing in these cells and the potential role it may play in diabetic
nephropathy.
MATERIALS AND METHODS
PODOCYTE CULTURE
Conditionally immortalized human podocytes retrovirally trans-
fected with the temperature-sensitive SV40 large T antigen gene
(Saleem et al., 2002) were routinely cultured as a monolayer at the
permissive temperature of 33◦C in a humidiﬁed atmosphere of 5%
CO2 and 95% air, with RPMI Medium 1640 (Life Technologies)
supplemented with heat-inactivated FBS (10% v/v; Life Technolo-
gies), D-glucose (5 mM; VWR), insulin (5 μg/ml)-transferrin
(5 μg/ml)-sodium selenite (5 ng/ml) media supplement (ITS;
Sigma–Aldrich), and L-glutamine (2 mM)-penicillin (100 U/ml)-
streptomycin (100 μg/ml) solution (PSG; Sigma–Aldrich) with
media changes occurring thrice weekly. Once conﬂuent, cells were
sub-cultured by aspirating media and incubating at 33◦C with
0.5% trypsin-EDTA solution [trypsin (5 g/l), Na2-EDTA (2 g/l),
NaCl (8.5 g/l); Life Technologies] for 4 min. The trypsin was neu-
tralized with normal culture media and cells were centrifuged at
350 × g for 6 min at room temperature. The cell pellet was re-
suspended in culture media; viable cells were counted using 0.4%
trypan blue solution (Sigma–Aldrich) andwere seeded at a density
of 10,000 cells/cm2 into cell culture-ware (BD Falcon). Podocytes
were terminally differentiated by incubating at the non-permissive
temperature of 37◦C for 14 days in a humidiﬁed atmosphere of
5% CO2 and 95% air with RPMI 1640 culture media (supple-
mented as above). All experiments were conducted in serum-free
conditions on terminally differentiated podocytes between pas-
sages 3 and 25 that had been subjected to serum starvation
overnight.
STIMULI AND INHIBITORS
Cellswere treated at 37◦Cwith the growth factor TGFβ1 (2.5 ng/ml
in serum-free media containing BSA (0.1% w/v); Sigma-Aldrich).
Inhibitors were applied at 37◦C in serum-free media. To dimin-
ish Erk5 activation the upstream activator Mek5 was chemically
inhibited by BIX02188 (10 μM) with an additional 60 min
pre-incubation. TGFβ1-mediated signaling was stopped with
SB431542 (10 μM; Sigma–Aldrich), targeting the type I TGFβ
receptor Alk5, with a further 30 min pre-incubation. Trans-
membrane receptor-induced Ras function was prevented with
an additional 30 min pre-incubation using farnesylthiosalicylic
acid (FTS; 10 μM; Cambridge Bioscience). Controls (vehi-
cles) were treated with serum-free media containing dimethyl
sulfoxide (DMSO; 0.1% v/v; Sigma–Aldrich) and BSA (0.1%
w/v).
CELL PROLIFERATION
The extent of cell proliferation was assessed using the colori-
metric CellTiter 96 AQueous Non-Radioactive Cell Proliferation
Assay (Promega). Cells were cultured in a 96-well plate (BD Fal-
con) and incubated with the appropriate treatments in a total of
100 μl of serum-free media. At the 48 h experiment end-point
1 ml of PMS [PMS (0.92 mg/ml) in Dulbecco’s PBS (DPBS);
KCl (0.2 g/l), NaCl (8.0 g/l), KH2PO4 (0.2 g/l), Na2HPO4
(1.15 g/l), MgCl2 (100 mg/l)·6H2O, CaCl2 (133 mg/l)·2H2O; pH
7.35] Solution was added to 20 ml MTS Solution and 20 μl of
this mixture was then combined with each well containing cells,
thereby producing ﬁnal concentrations of MTS (333 μg/ml) and
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PMS (25 μM). The cells were then incubated for 2 h at 37◦C
in a humidiﬁed atmosphere of 5% CO2 and 95% air. There-
after, the absorbance at 490 nm was measured with the Sunrise
microplate absorbance reader (Tecan) using the accompanying
XFluor4 software (v4.51; Tecan); the amount of the red for-
mazan product is directly proportional to the number of living
cells. Results were blanked against control wells without cells con-
taining 100 μl serum-free media and 20 μl combined MTS/PMS
solution.
CELL MOTILITY
The assessment of cellmotilitywas conductedusing a scratch assay.
Initially prior to differentiation, cells were allowed to proliferate to
achieve a conﬂuency greater than usual (>70%). After overnight
serum starvation culture media was removed and cells were sub-
jected to 60min pre-incubationwith BIX02188 (10μM)or vehicle
andmedia removed once again. A sterile 200μl pipette tip was uti-
lizedwith a smooth sweep across themonolayer. Cells werewashed
twice in media to remove debris, treatments applied, and 0 h base-
line images taken with light microscopy (Nikon). Experiments
were concluded by taking light microscopy images and were then
examined in ImageJ (v1.46; National Institute of Health). Color
images were converted to eight-bit gray scale and the denuded
area calculated with the “Polygon Selection Tool”; results were
normalized to area values at 0 h with a reduction in area indi-
cating increased motility due to cells migrating into the clear
zone.
BARRIER FUNCTION
Electric cell-substrate impedance sensing (ECIS)wasused to inves-
tigate barrier function. Monolayers of cells were grown in a 96
well ECIS array: cell culture-ware with a base comprised of gold
ﬁlm electrodes (20 electrodes/well) delineated with an insulat-
ing ﬁlm (Applied Biophysics). After treatment application the
ECIS array was seated in the ECIS Z instrument (Applied Bio-
physics) housed at 37◦C in a CO2 incubator with a humidiﬁed
atmosphere of 5% CO2 and 95% air. An alternating current (I)
of 4000 Hz was applied across the electrodes and the ensuing
electric potential difference (V ) created was recorded once per
minute, from which the impedance (Z) was calculated according
to Ohm’s law: Z = V / I. Cells covering the electrode surface per-
form as insulators and an increase in the distance between adjacent
cells caused by dysregulation of intercellular junctions decreased
the impedance witnessed which was used as a measure of bar-
rier function; results were normalized to baseline values recorded
at 0 h.
APOPTOSIS
Apoptosis was assessed by ﬂow cytometry with the TACS Annexin
V-FITC Kit (Trevigen) and necrotic cells were detected using 7-
Amino-Actinomycin D (7-AAD; BD Biosciences). After 48 h of
treatment, culture media was aspirated to collect dead cells and
dispensed into sterile 1.5 ml microcentrifuge tubes (Appleton
Woods). Dying as well as viable cells still adherent were incu-
bated at 37◦C with 0.5% trypsin-EDTA solution for 4 min, after
which the trypsinised cells were combined with the corresponding
culture media supernatants and FBS (1% v/v) was added. Cells
were then centrifuged at 400 × g for 6 min at 4◦C. To remove
EDTA, which would otherwise cause chelation of the calcium
necessary for binding of annexin V and phosphatidylserine, the
cells were re-suspended in 500 μl ice-cold PBS + FBS (1% v/v)
and once more centrifuged at 400 × g for 6 min at 4◦C. After
discarding the supernatant cells were re-suspended in 100 μl
Annexin V Incubation Reagent [Binding Buffer (1×), 7-AAD
(1 μg), Annexin V-FITC (1:10), in deionised H2O] for 30 min.
Thereafter, 400 μl Binding Buffer (1x) was added and 10,000
cells/sample were counted with a FACSCalibur ﬂow cytometer
(BD Biosciences) using the CellQuest Pro software (v5.2.1; BD
Biosciences).
WESTERN BLOTTING
Protein lysates were prepared on ice by aspirating the medium
and adherent cells were then rinsed in ice-cold PBS, removed with
a cell scraper in 70 μl lysis buffer [Tris-HCl (20 mM), pH 7.5,
NaCl (150 mM), EDTA (1 mM), Triton X-100 (1% v/v; Sigma–
Aldrich), sodium deoxycholate (0.5% w/v), SDS (0.1% w/v),
protease inhibitor cocktail (1×; Roche), phosphatase inhibitor
cocktail (2×; Roche)] and lysed with a vortex mixer for 10
s. Lysates were kept on ice for more than 15 min before cen-
trifugation at 10,000 × g for 10 min at 4◦C after which the
supernatant containing protein was aspirated and stored at –80◦C.
Protein concentrationswere determinedwith a colorimetric bicin-
choninic acid (BCA) protein assay kit (Pierce) and absorbance
was measured at 562 nm after incubating at 37◦C for 30 min
with the Sunrise microplate absorbance reader using the XFluor4
software.
Protein sampleswere prepared forwestern blotting under dena-
turing and reducing conditions by heating at 70◦C for 10 min
in a solution containing NuPAGE LDS Sample Buffer (1×; Life
Technologies) and NuPAGE Sample Reducing Agent (1×; Life
Technologies). Equal amounts of total protein were resolved by
size with electrophoresis on NuPAGE Novex 4–12% Bis-Tris gels
(Life Technologies) with NuPAGE MOPS SDS Running Buffer
(Life Technologies) using the XCell SureLock Mini-Cell tank (Life
Technologies) for 55 min at 200 V constant. Proteins were then
transferred onto Immobilon-P PVDF transfer membranes (Merck
Millipore) for 4 h at 30V constant inNuPAGETransfer Buffer (Life
Technologies) using the XCell II Blot Module (Life Technologies).
Post-transfer, membranes were washed for 10 min in tris-
buffered saline-Tween-20 [TBS-T; tris base (20 mM), NaCl
(137 mM), pH 7.6, Tween-20 (0.1% v/v; VWR)], blocked for
1 h in dried skimmed milk (5% w/v) in TBS-T followed by
3 × 5 min washes in TBS-T. Membranes were then incubated
overnight at 4◦C with the following primary antibodies: Erk5
(1:1000; New England Biolabs), Phospho-Erk5 (Thr218/Tyr220)
(1:1000; New England Biolabs), Phospho-p44/42 MAP kinase
(Erk1/2) (Thr202/Tyr204) (197G2) (1:1000; New England Bio-
labs); the loading control α-/β-tubulin (1:1000; New England
Biolabs) was incubated at room temperature for 1 h. After a
TBS-T wash procedure of 10 min and then 3 × 5 min, membranes
were incubated at room temperature on a 3D gyratory rocker for
1 h with the Anti-Rabbit IgG HRP-linked Antibody (1:2000; New
England Biolabs), and were then washed in TBS-T for 10 min fol-
lowed by 3 × 5 min. Membranes were incubated for 5 min with
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Solution A:Solution B (1:1) of the Amersham ECL Prime west-
ern blotting detection reagent kit (GE Healthcare Life Sciences).
The membranes were then exposed to Amersham Hyperﬁlm ECL
(GE Healthcare Life Sciences) ﬁlms and subsequently developed
using the MI-5 X-ray ﬁlm processor (VWR). Western blot ﬁlms
were imaged with the ImageQuant 300 imager and ImageQuant
Capture software (v1.0.0.4; GE Healthcare Life Sciences). Quan-
tiﬁcation was conducted by performing densitometry with the
ImageQuant TL software (v1.1.0.4; GE Healthcare Life Sciences)
where target protein band intensity was expressed relative to that
of the corresponding loading control.
IMMUNOFLUORESCENCE
At the experimental end-points, media was aspirated and cells
were washed with warm PBS. Cells were then ﬁxed and perme-
abilised with ice-cold methanol for 15 min at –20◦C followed
by removing the methanol and rehydrating in PBS for 15 min.
Cells were incubated in blocking buffer [Triton X-100 (0.2% v/v),
serum (5% v/v) derived from the species of the primary anti-
body in PBS] for 1 h at room temperature before being rinsed
in PBS and incubating overnight at 4◦C with the following pri-
mary antibodies: Human/Mouse Erk5/BMK1 (15 μg/ml; R&D
Systems), P-Cadherin (1:100; Insight Biotechnology),Monoclonal
Anti-α-Smooth Muscle Actin Clone 1A4 (1:200; Sigma–Aldrich),
Synaptopodin (H-140; 1:50; Insight Biotechnology), diluted in
primary antibody dilution buffer [Triton X100 (0.2% v/v) in PBS].
The following day cells were subjected to 3 × 5 min washes in
PBS prior to incubating in darkness at room temperature for 1 h
with the following ﬂuorochrome-conjugated secondary antibod-
ies diluted in secondary antibody dilution buffer [Triton X-100
(0.2% v/v), and DAPI in PBS]: Alexa-Fluor 488 Donkey Anti-
Goat IgG (H+L) (1:200; Life Technologies), Alexa-Fluor 555 Goat
Anti-Mouse IgG (H+L) (1:200; Life Technologies), Alexa-Fluor
555 Goat Anti-Rabbit IgG (H+L) (1:200; Life Technologies). Cells
were washed for 3 × 5 min in PBS and subsequently covered
in mounting buffer [90% glycerol (Sigma–Aldrich) in de-ionized
H2O] before examination with an inverted ﬂuorescent micro-
scope (Nikon) at the appropriate excitation wavelength using the
NIS-Elements imaging software (Nikon). Cells were stored at 4◦C
protected from light.
STATISTICAL ANALYSIS
Quantitative data are presented as means ± standard error of the
mean (SEM). Statistical analysis was conducted using one-way
analysis of variance (ANOVA) with Tukey’s multiple comparison
post hoc test when more than two groups were being analyzed
simultaneously andwhen two groups were being analyzed a paired
t-test was conducted with the statistical software GraphPad Prism.
Differences were considered statistically signiﬁcant at values of
P < 0.05 denoted by a single asterisk (∗), P < 0.01 denoted by
a double-asterisk (∗∗) and P < 0.001 denoted by a triple-asterisk
(∗∗∗).
RESULTS
Erk5 EXPRESSION IN HUMAN PODOCYTES
Erk5 protein expression was investigated due to the absence of
any published previous investigation. Indeed, western blotting
revealed the expression of Erk5 in conditionally immortal-
ized human podocytes (Figure 1A). Following 5 min TGFβ1
(2.5 ng/ml) treatment at 37◦C in the absence of serum podocytes
exhibited three bands recognized by a phospho (p)-Erk5 antibody
(Thr218/Tyr220) at ∼120, ∼80, and ∼75 KDa, which paral-
leled the three splice variants of Erk5 that exist: Erk5a, Erk5b,
and Erk5c; expression was dependent on the upstream Mek5 as
60 min pre-incubation and co-treatment with the Mek5 chemi-
cal inhibitor BIX02188 (10 μM) prevented Erk5 phosphorylation
(Figure 1A). BIX02188 at 10 μM had no effect on p-Erk1/2 in
these cells. Immunoﬂuorescence depicted the basal subcellular
localization of Erk5 to be predominantly nuclear and BIX02188
reduced the diffuse staining present in the cytoplasm (Figure 1D).
Stimulation with TGFβ1 for 5 min increased the cytoplasmic
staining of Erk5 (Figure 1D). BIX02188 5 min co-treatment
reduced Erk5 cytoplasmic staining and to lesser extent nuclear
staining as evinced by a greater proportion of cells with nuclei
that predominantly exhibited DAPI staining over Erk5 staining
(Figure 1D). TGFβ1-induced Erk5 activation at 5 min was Alk5-
dependent as a 30 min pre-incubation and 5 min co-incubation
with the TGFβ type I receptor inhibitor SB431542 (10 μM)
reduced p-Erk5 levels (Figure 1B). However, pre-incubation for
30 min and subsequent co-incubation with FTS (10 μM) had no
effect, demonstrating no involvement of the small GTPase Ras
(Figure 1C).
PODOCYTE PROLIFERATION
Podocytes are terminally differentiated cells that do not proliferate
under normal physiological conditions. To assess the proliferation
of podocytes in response to the pro-ﬁbrotic stimulus of TGFβ1,
podocytes were pre-incubated in the presence and absence of
BIX02188 (10 μM) for 60 min after which cells were co-treated
with TGFβ1 (2.5 ng/ml) for 48 h to provide adequate time for
proliferation to occur and a colorimetric cell proliferation assay
was employed where metabolic activity is directly proportional to
cell number. Inhibition of Erk5 activation with BIX02188 incuba-
tion reduced podocyte cell number (Figure 2). TGFβ1 stimulation
increased podocyte cell number which was prevented following
BIX02188 co-treatment (Figure 2).
PODOCYTE MOTILITY
An investigation into the involvement of Erk5 in regulating
podocyte motility was conducted with a scratch assay where cells
were pre-incubated for 60 min with BIX02188 (10 μM) and sub-
sequently cells were removed from a conﬂuent monolayer and the
extent of cell migration into the denuded area was calculated fol-
lowing treatment with TGFβ1 (2.5 ng/ml) for 12 h as this provides
sufﬁcient time for migration to occur without the recorded area
reaching saturation. TGFβ1 stimulation for 12 h reduced podocyte
motility, as did Mek5 inhibition, relative to control treated cells
that exhibited migration (Figure 3).
PODOCYTE BARRIER FUNCTION
To observe the role that Erk5 activity imparts on podocyte bar-
rier function cells were grown on an electrode-coated surface and
impedance across the cell layer was measured by ECIS. Podocytes
were pre-incubated for 60 min with the Mek5 inhibitor BIX02188
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FIGURE 1 | Erk5 expression, activation, and subcellular localisation in
podocytes via TGFβ1. (A) Representative western blot of p-Erk5, Erk5, and
p-Erk1/2 protein expression in conditionally immortalized human podocytes
pre-incubated for 60 min with the Mek5 inhibitor BIX02188 (10 μM)
followed by co-incubation with TGFβ1 (2.5 ng/ml) for 5 min. Podocytes
expressed Erk5 protein and TGFβ1 signiﬁcantly increased protein levels of
p-Erk5b (P < 0.05), whilst BIX02188 co-treatment reduced Erk5 activation
in response to TGFβ1 (P < 0.05); Erk5 was used as a loading control; paired
t -test, n = 3. Levels of p-Erk1/2 did not signiﬁcantly decrease with
BIX02188 co-treatment relative to the TGFβ1 stimulus; α-/β-tubulin was used
as a loading control; one-way ANOVA with Tukey’s multiple comparison post
hoc test, n = 3. (B) Representative western blot of p-Erk5, Erk5, and
p-Erk1/2 protein expression in podocytes pre-incubated for 30 min with the
Alk5 inhibitor SB431542 (10 μM) followed by co-incubation with TGFβ1
(2.5 ng/ml) for 5 min. SB431542 decreased p-Erk5 levels both in
non-stimulated and TGFβ1-stimulated cells (P < 0.05); Erk5 was used as a
loading control; paired t -test, n = 3. (C) Representative western blot of
p-Erk5, Erk5, and p-Erk1/2 protein expression in podocytes pre-incubated for
30 min with the Ras inhibitor FTS (10 μM) followed by co-incubation with
TGFβ1 (2.5 ng/ml) for 5 min. Levels of p-Erk5 did not change signiﬁcantly
following Ras inhibition; Erk5 was used as a loading control; paired t -test,
n = 3. (D) Immunoﬂuorescence staining of Erk5 in podocytes pre-incubated
for 60 min with BIX02188 (10 μM) followed by co-incubation with TGFβ1
(2.5 ng/ml) for 5 min. Erk5 was mainly, but not exclusively localized to the
nucleus and BIX02188 treatment reduced the diffuse staining present in the
cytoplasm. TGFβ1 stimulation increased the diffuse cytoplasmic staining and
following BIX02188 co-treatment this was reduced which additionally
slightly reduced nuclear Erk5 staining.
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FIGURE 2 | Regulation of podocyte proliferation via Erk5. Colorimetric
cell proliferation assay investigating proliferation of podocytes pre-
incubated for 60 min with the Mek5 inhibitor BIX02188 (10 μM) followed by
co-incubation with TGFβ1 (2.5 ng/ml) for 48 h. TGFβ1 induced podocyte
proliferation which was prevented with BIX02188 co-treatment.
**P < 0.01, ***P < 0.001; paired t -test, n = 6.
(10 μM) followed by co-incubation with TGFβ1 (2.5 ng/ml) for
6 h to allow morphological changes to initiate whilst avoiding
observations that could be attributed to changes in cell num-
ber. TGFβ1 reduced transcellular impedance, andMek5 inhibition
decreasedbarrier function innon-stimulated conditionswhilst co-
treatment with TGFβ1 restored barrier function to control levels
(Figure 4).
PODOCYTE PHENOTYPE
The role of Erk5 in TGFβ1-mediated changes in podocyte phe-
notype was explored with immunoﬂuorescence to study the
expression and subcellular localization of the podocyte marker
synaptopodin, P-cadherin as an epithelial cell marker and α-
smooth muscle actin (α-SMA) as a mesenchymal cell marker.
Podocytes were pre-incubated with the Mek5 inhibitor BIX02188
(10 μM) for 60 min followed by subsequent co-incubation with
TGFβ1 (2.5 ng/ml) for 48 h. Synaptopodin was concentrated
in the nucleus with diffuse staining in the cytoplasm under
non-stimulated conditions (Figure 5A). BIX02188 treatment
alone did not affect synaptopodin subcellular localization, whilst
TGFβ1 treatment increased cytoplasmic staining and co-treatment
prevented this increase (Figure 5A). Podocytes demonstrated
punctate nuclear staining of P-cadherin and TGFβ1 treatment
decreased the expression observed relative to the non-stimulated
control (Figure 5B). BIX02188 treatment alone increased nuclear
staining relative to the control and TGFβ1 co-treatment prevented
the TGFβ1-induced reduction (Figure 5B). Under non-stimulated
FIGURE 3 | Regulation of podocyte motility via Erk5. Podocytes
pre-incubated for 60 min with the Mek5 inhibitor BIX02188 (10 μM), after
which the monolayer was scratched and subsequently co-treated with
TGFβ1 (2.5 ng/ml) for 12 h. Inhibition of Erk5 activity decreased podocyte
motility as did TGFβ1 treatment and co-treatment further augmented the
reduction in motility observed; data normalized to the denuded area
measured at 0 h. *P < 0.05; paired t -test, n = 3.
conditions there was weak punctate nuclear staining of α-SMA
and faint diffuse staining in the cytoplasm (Figure 5C). BIX02188
treatment alone increased the nuclear staining observed, whilst
also reducing the cytoplasmic staining (Figure 5C). TGFβ1
increased the nuclear staining intensity and greatly increased
the cytoplasmic staining which was prevented with BIX02188
co-treatment (Figure 5C).
PODOCYTE APOPTOSIS
The loss of podocytes is a key aspect of diabetic nephropathy and
a variety of factors have been implicated, most notably TGFβ1
(Dessapt et al., 2009). To explore apoptosis podocytes were pre-
incubated with BIX02188 (10 μM) prior to TGFβ1 (2.5 ng/ml)
co-treatment for 48 h and subjected to analysis by ﬂow cytometry
for the externalization of phosphatidylserine which occurs as part
of the apoptotic process. Inhibiting Erk5 activity resulted in an
increase in podocyte apoptosis (Figure 6). TGFβ1 treatment also
produced an increase in podocyte apoptosis as did co-treatment
with BIX02188 (Figure 6).
DISCUSSION
Since the ﬁrst report of Erk5 (Zhou et al., 1995) there has
been an ever growing interest in its potential role in physiol-
ogy and pathology. The conventional Erk5 knock-out mouse
demonstrated embryonic lethality, highlighting its importance,
and Erk5 was strongly implicated in cardiovascular development
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FIGURE 4 | Regulation of podocyte barrier function via Erk5. (A,B)
Podocytes pre-incubated for 60 min with the Mek5 inhibitor BIX02188
(10 μM) followed by co-incubation with TGFβ1 (2.5 ng/ml) for 6 h and
subjected to ECIS where transcellular impedance was measured. TGFβ1
reduced podocyte transcellular impedance. BIX02188 treatment alone
decreased barrier function, whereas co-treatment with TGFβ1
signiﬁcantly increased barrier function thereby restoring it to control
levels. (B) 6 h end-point representation of ECIS readout; data
normalized to baseline values recorded at 0 h. *P < 0.05, **P < 0.01;
paired t -test, n = 6.
and angiogenesis due to a loss of vascular integrity through
increased endothelial cell apoptosis (Regan et al., 2002; Hayashi
et al., 2004). Subsequently, the critical role for Erk5 in cell survival
and proliferation suggested it as a possible target for cancer ther-
apies (Winn et al., 2006). Suzaki et al. (2004) identiﬁed a potential
role for Erk5 in the pathogenesis of the diabetic kidney describing
increased activation of Erk5 in the glomeruli of diabetic rats and
using in vitro techniques to demonstrate its activation in mesan-
gial cells by high glucose. The signiﬁcant role that Erk5 might
possess in diabetic nephropathy was furthered in later reports by
our group and others of TGFβ1-mediated activation of Erk5 in
both renal tubule epithelial cells andmesangial cells (Browne et al.,
2008; Dorado et al., 2008). However, hitherto the work detailed
herein there have been no reports of its expression or activa-
tion in podocytes, a cell now considered central in diabetic renal
injury.
Here we describe the presence in transformed human
podocytes of three splice variants of Erk5 as depicted by the expres-
sion of three p-Erk5 protein bands. As in other renal cells we
were able to demonstrate the phosphorylation on Thr218/Tyr220,
the proposed target for the upstream activator Mek5. We con-
ﬁrmed this by the use of the selective Mek5 inhibitor BIX02188
and also established that the activationwas dependent on theTGFβ
type I receptor, Alk5. However, it cannot be concluded from our
work which isoform or isoforms may be responsible for the spe-
ciﬁc activities observed. Alternative splice variants from the same
gene often have opposing actions and any proposition to manip-
ulate the Mek5/Erk5 axis should be preceded by an investigation
involving alternative splicing. Interestingly, TGFβ1-mediated Erk5
activation did not involve Ras as FTS treatment did not alter Erk5
phosphorylation, thus emphasizing the cell type-speciﬁc nature of
Erk5 signaling given that Ras involvement is inconsistent between
a selection of cancer cell lines (Drew et al., 2012).
Podocyte proliferation and apoptosis in response to TGFβ1 has
been described previously by Herman-Edelstein et al. (2011),
however, their work did not seek to investigate the molecular
mechanisms responsible. Here we replicate their observation but
further identify that these are by differing cell signaling pathways.
TGFβ1-inducedproliferation of podocyteswas signiﬁcantly inhib-
ited by blocking Erk5 phosphorylation, however, TGFβ1-induced
apoptosis was unaffected. Changes in podocyte phenotype were
consistent with the changes in barrier function observed follow-
ing TGFβ1 treatment, and both were markedly attenuated by Erk5
inhibition; a concomitant reduction of P-cadherin and increased
α-SMA with TGFβ1 stimulation is consistent with a transgres-
sion of phenotype which was reversed through the inhibition of
Erk5 activation. Although controversy surrounds epithelial-to-
mesenchymal transition regarding podocytes, Herman-Edelstein
et al. (2011) better characterized the process as dedifferentiation.
Podocytes aremore akin to pericytes rather than being true epithe-
lial cells and the changes induced by TGFβ1 in podocytes are not
typical of epithelial-to-mesenchymal transition, speciﬁcally the
suppression of proliferation and the reduction in tight junction
formation was not observed. The unique structure and phenotype
of podocytes is what allows them to precisely regulate glomeru-
lar barrier function; it is not proposed that the barrier function
observed here in vitro is exactly the same. Glomerular barrier
function in vivo is potentially affected by a number of factors,
for example the experiments conducted herein did not replicate
the pressure of ﬂuid as would be exerted from the blood vessels
along with the ensuing signaling that results from shear stress.
The loss of the specialized podocyte phenotype that is reported
here would be consistent with cytoskeletal changes resulting in
the ﬂattening and loss of podocyte foot processes, a phenotype
which is associated with proteinuria in vivo; this can be witnessed
in an elegant time-lapse by Herman-Edelstein et al. (2011). The
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FIGURE 5 | Continued
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FIGURE 5 | Continued
Regulation of podocyte phenotype withTGFβ1 via Erk5.
(A) Immunoﬂuorescence staining of synaptopodin in podocytes
pre-incubated for 60 min with the Mek5 inhibitor BIX02188 (10 μM)
followed by co-incubation with TGFβ1 (2.5 ng/ml) for 48 h. Synpatopodin
staining was greatest in the nucleus with diffuse cytoplasmic staining.
BIX02188 treatment alone did not affect synaptopodin localization, whilst
TGFβ1 treatment increased cytoplasmic staining and co-treatment reduced
this increase. (B) Immunoﬂuorescence staining of P-cadherin in podocytes
pre-incubated for 60 min with the Mek5 inhibitor BIX02188 (10 μM)
followed by co-incubation with TGFβ1 (2.5 ng/ml) for 48 h. P-cadherin
exhibited punctate nuclear staining in the non-stimulated control andTGFβ1
treatment decreased the expression observed. BIX02188 treatment alone
increased nuclear staining relative to the control andTGFβ1 co-treatment
prevented theTGFβ1-induced reduction. (C) Immunoﬂuorescence staining
of α-SMA in podocytes pre-incubated for 60 min with the Mek5 inhibitor
BIX02188 (10 μM) followed by co-incubation with TGFβ1 (2.5 ng/ml) for
48 h. There was weak punctate nuclear staining of α-SMA and faint diffuse
cytoplasmic staining under non-stimulated conditions. BIX02188 treatment
alone increased the nuclear staining, whilst also reducing the cytoplasmic
staining. TGFβ1 increased the nuclear staining intensity and increased the
cytoplasmic staining which was prevented with BIX02188 co-treatment.
observed ﬂattening following TGFβ1 masked the reduction in
barrier function detected as determined with ECIS, since the
increased cell surface area enhances the impedance conferred by
the monolayer, hence the limited reduction with TGFβ1. With this
consideration it would appear from our work that TGFβ1 has the
potential to modify the specialized phenotype of the podocyte in
a manner likely to alter its function, and consequently still repre-
sents a loss of barrier function which can be mitigated to a large
extent by inhibiting the activation of Erk5 by Mek5.
One of the early reports of TGFβ-mediated activation of
Erk5 indicated that the kinase was required for protein stabiliza-
tion of the Snail transcription factor (Marchetti et al., 2008), a
process known to be involved in the regulation of cell differen-
tiation along with epithelial-to-mesenchymal transition and was
recently demonstrated in nephrin loss from podocytes (Gagliar-
dini et al., 2013). The agonist used in the work by Gagliardini
et al. (2013) was Angiotensin II, another known activator of Erk5
and a target in diabetic nephropathy. Although our work did not
speciﬁcally address molecular mediators downstream of Erk5, this
FIGURE 6 | Regulation of podocyte apoptosis via Erk5. (A,B) Flow
cytometry analysis of podocytes pre-incubated for 60 min with the Mek5
inhibitor BIX02188 (10 μM) followed by co-incubation with TGFβ1 (2.5 ng/ml)
for 48 h. Inhibition of Erk5 activation increased podocyte apoptosis which
also occurred followingTGFβ1 stimulation as well as co-treatment.
(B) Representation of apoptotic cells located in Q3 seen above.
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could be a potential mechanism in the regulation of podocyte
phenotype.
As stated above, diabetic nephropathy is a disease associated
with marked podocyte dysfunction, but it is also characterized by
extensive renal ﬁbrosis. Consequently, the work by Dorado et al.
(2008) describing the role of Erk5 in mediating TGFβ-induced
collagen I production in mesangial cells is of considerable inter-
est in the context of our own work; Erk5 may prove to be a
key target in controlling the multiple cellular processes that con-
stitute diabetic nephropathy. In pulmonary ﬁbrosis Erk5 also
appears to be necessary for the production of ECM by ﬁbrob-
lasts and epithelial cells, however, in this case it is associated with
Smad3 acetylation; acetylation of Lys19 on Smad3 enhances the
binding of Smad3 to DNA (Kim et al., 2013). The activation of
Erk5 by glucose in retinal and vascular endothelial cells causes
a signiﬁcant rise in ﬁbronectin expression, a feature of diabetic
retinopathy (Wu et al., 2012). Interestingly, in these experiments
the effect of Erk5 may be Smad-independent as expression of con-
stitutively active Erk5 was associated with a decrease in Smad2
phosphorylation. TGFβ-induced ﬁbronectin expression in human
renal proximal tubule epithelial cells is also Smad-independent
whilst being p38-dependent, thus targeting MAP kinase-mediated
control of ECM production would be valuable in disease
(Niculescu-Duvaz et al., 2007).
Despite the evidence above, the therapeutic down-regulation
of Erk5 remains controversial, perhaps particularly in diabetes
largely because of the suspected effects on endothelial cells. It
is certainly true that the phenotypes of the embryos from Erk5
knock-outmice demonstrate that Erk5 is vital for the development
of the endothelium (Regan et al., 2002). There is also evidence
that shear force activates Erk5 in endothelial cells and that this is a
protective mechanism inhibiting apoptosis (Shishido et al., 2008).
Furthermore, Shishido et al. (2008) asserted that loss of Erk5 tran-
scriptional activity through conjugation of small ubiquitin-like
modiﬁer (SUMO) in amechanism termed SUMOylation, induced
at least in part by AGEs resulting from diabetes, is deleterious
(Woo et al., 2008). However, the groups do provide evidence to
support their assertion that SUMOylation does not alter Erk5
phosphorylation or kinase activity but does inhibit transcription
of certain Erk5 targets, such as KLF2. The work suggests that the
effect of SUMOylation on Erk5 activation of the KLF2 promoter
is independent of Erk5 phosphorylation. However, the current
received wisdom is that Erk5 activation of transcription requires
phosphorylation; therefore inhibition of Erk5 phosphorylation
on Thr218/Tyr220 would also inhibit KLF2 promoter activity and
eNOS expression. What is not clear is whether the anti-podocyte
effects of TGFβ1 mediated by Erk5 described in this manuscript
require transcription, as this was not within the remit of this inves-
tigation orwhether othermechanisms such as protein stabilization
or acetylation may be involved.
CONCLUSION
These results describe for the ﬁrst time the expression of Erk5 in
podocytes and strongly supports Erk5 as a mediator to TGFβ-
induced loss of podocyte phenotype and function and, in the
context of other work, potentially demonstrates a pro-ﬁbrotic
effect of TGFβ1 being mediated by Erk5 thereby suggesting that
Erk5 should be considered a novel target in diabetic renal disease.
However, the evidence that loss of certain transcriptional activity
of Erk5 may be harmful requires that further investigation is car-
ried out into the precise mechanism in which Erk5 regulates the
complex nature of podocyte phenotype and barrier function.
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